INMED PHARMACEUTICALS INC. Production Costs, Period Cost
INMED PHARMACEUTICALS INC. (INM) reported Production Costs, Period Cost of $900.00 thousand for the 6-month period ending 2023-12-31, per its 10-Q filed 2024-02-13.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ProductionCosts · last filed 2024-02-13
- INMED PHARMACEUTICALS INC. production costs, period cost for the quarter ending 2023-03-31 was -$81.44K.
- INMED PHARMACEUTICALS INC. production costs, period cost for the quarter ending 2022-12-31 was -$36.91K.
- INMED PHARMACEUTICALS INC. production costs, period cost for the quarter ending 2022-09-30 was $563.61K.
| Period end | Production Costs, Period Cost 3 month | Production Costs, Period Cost 6 month | Production Costs, Period Cost 9 month |
|---|---|---|---|
| 2023-12-31 | $900.00K 10-Q · filed 2024-02-13 | ||
| 2023-03-31 | -$81.44K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-15 | -$118.35K derived: sum of 2 quarters · filed 2023-05-15 | $445.26K 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$36.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-02-17 | $526.70K 10-Q · filed 2023-02-17 | |
| 2022-09-30 | $563.61K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |